InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（1 笔）
内部人交易记录
首席财务官已披露买入
0
已披露卖出
1
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the complete record of transactions filed by Fenton Mary Kay, 首席财务官. Insider active across 2 companies, notably Talaris Therapeutics, Inc.. In total, 7 filings have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €51k. History available since 31 December 2021. The latest transaction was disclosed on 20 February 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Fenton Mary Kay
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报7 总计
4,398 股@ US$13.6299.7% 占其流量Common StockSEC:0001193125-26-064261:0
68,750 股0Common StockSEC:0001193125-26-059637:0
27 股@ US$6.490.3% 占其流量Common StockSEC:0001193125-26-002687:0
60,000 股0Common StockSEC:0000950170-25-025027:0
12,946 股@ US$3.0861.4% 占其流量Common StockSEC:0001209191-23-041617:0
80,000 股0Common StockSEC:0000899243-22-030928:0
1,000 股@ US$13.0023.9% 占其流量Common StockSEC:0000899243-22-004201:0
7 条申报中的 7 条
About Fenton Mary Kay
Fenton Mary Kay is Chief Financial Officer at Cullinan Therapeutics, Inc. and Talaris Therapeutics, Inc. She has 7 filings in total. Across the 7 sampled filings, the period runs from 2022-02-02 to 2026-02-23, with 0 in buys and 50896 in sells, and the most common transaction nature is Attribution.
